This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision |
| ocular_complications_chemotherapeutic_agents [2024/05/17 14:21] – Scott Larson | ocular_complications_chemotherapeutic_agents [2025/06/14 02:59] (current) – [References] Scott Larson |
|---|
| |
| ====References==== | ====References==== |
| * {{::ocular_toxicity_of_mek_inhibitors_and_other_targeted_therapies.pdf |Ocular toxicities of MEK inhibitors and other targeted therapies. Stjepanovic et al. Annals of Oncology.Volume 27, Issue 6, June 2016, Pages 998-1005}} | * [[https://1drv.ms/b/c/31d83ae8e55e0542/ERC5LNJpRMBEuMqgnPkrivMBz0aY8tspvomR00t6YZzhng?e=BaC6F7|Ocular toxicities of MEK inhibitors and other targeted therapies. Stjepanovic et al. Annals of Oncology.Volume 27, Issue 6, June 2016, Pages 998-1005]] |
| * {{::clinical_and_morphologic_characteristics_of_mek_inhibitor-associated_retinopathy.pdf |Clinical and Morphological Characteristics of MEK Inhibitor-Associated Retinopathy. Francis, Jasmine H. et al. Ophthalmology. 2017-12, Vol.124 (12), p.1788-1798 }} | * [[https://1drv.ms/b/c/31d83ae8e55e0542/EYA8uzBJ-_BBiRnZReDu7NUBqsbAxKVJqHK3n-dqPKIwmw?e=DZwwKg |Clinical and Morphological Characteristics of MEK Inhibitor-Associated Retinopathy. Francis, Jasmine H. et al. Ophthalmology. 2017-12, Vol.124 (12), p.1788-1798]] |